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Introduction:  In  2012,  an increase  in  mumps  notiﬁcations  occurred  in  Belgium,  affecting  young  vaccinated
adults.  At  the end  of 2012,  a mumps  outbreak  occurred  at the  Catholic  University  of Leuven  KU  Leuven in
Flanders.  We  investigated  the  outbreak  to estimate  incidence,  mumps  vaccine  effectiveness  and  to  detect
potential  risk  factors  for the disease.
Methods:  In June  2012,  we  set up  mandatory  notiﬁcation  in Flanders  and  we collected  information  on
circulating  genotypes  from  the National  Reference  Centre.  We  conducted  a cohort  study  among  KU  Leu-
ven students.  We  deﬁned  a case  as  self-reported  parotitis,  between  September  2012  and  March  2013.
We  distributed  web-based  questionnaires  to  a  random  sample  of students.  We  calculated  vaccine  effec-
tiveness  by  comparing  the  risks  in  students  vaccinated  twice  with  those  vaccinated  once.  We  estimated
risk  ratios  (RR)  to  identify  risk  factors.
Results:  From  16th  June  2012  to  1st April  2013,  4061  mumps  cases  were  notiﬁed  to the  regional  public
health  ofﬁce  (30% were  vaccinated  once  and  69%  were  vaccinated  twice).  All  16  samples  collected  at
the  KU  Leuven  were  genotype  G5.  Of  717  participants  of  the  cohort  study,  38 (5%;  95%CI  4–8%) met
the  case-deﬁnition.  All  reported  being  vaccinated  with  at least  one  dose  of  mumps-containing  vaccine.
The  incidence  of  mumps  was  5% among  those  vaccinated  twice  and 16% among  those  vaccinated  once
(vaccine  effectiveness  of two  doses  compared  to one:  68%,  95%CI  −24% to 92%).  The  risk  of  mumps  was
lower  among  those  vaccinated  with  two  doses  of mumps-containing  vaccine  ≤10  years  before  (RR:  0.33,
95%CI  0.10–1.02)  and  higher  among  students  working  in  a bar  (RR:  3.6,  95%CI  1.8–7.0).
Conclusions:  Incomplete  protection  by  two doses  of  mumps-containing  vaccine,  possible  waning  immu-
nity  and  intense  social  contacts  may  have  contributed  to the  occurrence  of  this  outbreak  in Flanders.
Efforts  to  maintain  high  vaccination  coverage  with  two doses  remain  essential.  However,  the  reasons
for  low  vaccine  effectiveness  must  be further  explored  and additional  immunological  research  for  more
immunogenic  mumps  vaccines  is necessary.
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. Introduction
Mumps, a viral infection, can cause mild to severe symptoms
r be asymptomatic. The most characteristic feature of the dis-
ase is parotitis and swelling of the salivary glands. The risk of
evere symptoms and complications increases in adults [1]. Seque-
ae include meningitis (1–10%), encephalitis (0–1%), oophoritis
5% of female cases), orchitis (15–30% of male cases), pancreati-
is (4%) and deafness (0.005%) [1,2]. Mumps  basic reproduction
umber ranges from 4 to 10, which is lower than measles [3].
ased on 2004 WHO  data, 38% of the countries/areas world wide
se mumps  vaccine in their national immunization programmes.
mong these, 63% use a one dose schedule and 37% use a two-
ose vaccination schedule [4]. The introduction of mumps  vaccine
ed to a decrease in reported rates. In countries using two  doses
e.g., Norway, Denmark, Finland), rates decreased to <1/100,000
opulation. Seroconversion rates for one dose of the Jeryl Lynn
train mumps  vaccine, used in the vaccination schedule in Flan-
ers in Belgium, ranges from 80 to 100% [5]. Pre-licensure studies
stimated that the efﬁcacy of two doses Jeryl Lynn strain mumps
accine reached 95%. However, during outbreaks, vaccine effective-
ess for two doses ranged from 61% to 91% [6].
In 2002, the WHO  European Region introduced a strategic plan
o eliminate measles and prevent congenital rubella infection by
010. The plan involved increasing vaccine coverage with the
easles, mumps, rubella (MMR)  vaccine to at least 95%. Hence, a
arallel aim was to reduce annual reported rates for mumps  to
nder 1/100,000 by country [4]. From 2006 to 2010, in Europe,
umps  rates decreased from 8.7 to 1.98/100,000 [7]. However, at
he same time, several countries reported large outbreaks [8–13].
rom 2004 to 2005 on, one of the ﬁrst large mumps outbreaks in a
accinated population occurred in England and Wales [8], includ-
ng 2,562 laboratory conﬁrmed cases in 2012 [14]. From 2009, the
etherlands reported a mumps  outbreak that started among stu-
ents and evolved into a large national outbreak with 1662 cases
ntil June 2013 [15]. These outbreaks and other outbreaks, such
s those in the United States, shared common features [9]. First,
oung adults were most commonly affected. Second, cases clus-
ered among students with intensive social contacts (e.g., classes,
hared living facilities). Third, affected young adults were often
accinated with two-doses of mumps  vaccine.
In 1984, the general Flemish vaccination scheme included MMR
accination with a ﬁrst dose administered at the age of 10–12
onths. In 1995, a second dose administered at the age of 10–12
ears was added. The vaccination strain used in Flanders is Jeryl
ynn (MMRVax®, Priorix®) [16]. The vaccination coverage for chil-
ren aged 18–24 months (ﬁrst dose of MMR)  and children aged
4 years (second dose of MMR)  is estimated in Flanders using two-
tage cluster sampling surveys, that take place every 4–5 years. The
ost recent coverage assessment was performed in 2012 [17].
In Belgium, incidence of mumps  prior to general vaccination
as estimated at 500/100,000 in 1985 and declined to 49/100,000
n 1994 [16]. Mumps  is not a notiﬁable disease in Belgium. How-
ver, in Flanders, the regional public health ofﬁce requires medical
octors and authorities of educational institutions to notify clus-
ers of several diseases, including mumps. Between 1995 and 2010,
maller clusters of mumps  cases and one outbreak in 1995/96 in
artly vaccinated children aged 8–12 years were reported [6]. In
he spring of 2011, regional public health authorities of Antwerp (a
rovince of Flanders) reported a mumps  outbreak with 164 cases,
ostly among young adults [18]. In 2012, medical doctors from
hent reported a new cluster of mumps  among students of the
niversity [19]. This outbreak spread to campuses and universi-
ies in other provinces. However, the absence of a comprehensive
urveillance system prevented a full description of the disease bur-
en and of the characteristics of mumps  patients. On 16th of June (2014) 4393–4398
2012, after a risk assessment meeting ordered by the Flemish Min-
istry of Health, mandatory notiﬁcation for mumps was  introduced.
The system of mandatory notiﬁcation already existed for 35 infec-
tious diseases and applied to every physician and clinical laboratory
[20]. At the end of 2012, the medical service of the Catholic Uni-
versity of Leuven (KU Leuven), the largest university of Flanders
(37,742 students), informed the regional public health service of a
peak of mumps  related consultations. We  aimed to estimate the dis-
ease burden, describe the characteristics of cases, estimate vaccine
effectiveness and identify risk factors for the disease.
2. Methods
In order to describe the situation of mumps  in Flanders, Belgium,
we present two related, but separate analyses , the epidemiology of
mumps  over all of Flanders by surveillance data collected through
temporary mandatory notiﬁcation, from June 2012 to April 2013
and a retrospective cohort study among one of the affected univer-
sities.
2.1. Surveillance data
2.1.1. Epidemiological methods
For the purpose of surveillance, a case was deﬁned as a person
who presented with uni- or bilateral swelling of the parotid or other
salivary glands for more than two days without another apparent
cause (possible case) and epidemiological link with another mumps
case (probable case) and/or laboratory criteria by either detecting
the mumps  virus by PCR, mumps  IgM antibodies or detecting a four-
fold increase in mumps IgG antibodies (laboratory-conﬁrmed case).
Regional public health ofﬁcers collected information on patient
characteristics, symptoms, complications and self-reported vacci-
nation status and stored it in a database common for Flanders. The
mandatory notiﬁcation of mumps was  temporary and started on
16th of June 2012.
2.1.2. Laboratory investigations
Local health care providers collected oral ﬂuid and serum sam-
ples and delivered them to the national Reference Centre (NRC). The
reference centre received samples from all over Flanders. Analyses
were done using an in-house developed real-time PCR targeting the
SH protein from the mumps virus. Genotyping was also performed
using an in-house developed test on saliva and nasopharyngeal
secretions.
2.2. Retrospective cohort study
2.2.1. Study design and study population
We conducted a retrospective cohort study among students of
the KU Leuven. We  calculated the required sample size under the
following assumptions; if we want to detect a difference as small
as 5% in attack rate between those vaccinated and those unvac-
cinated and we  are willing to assume that the attack rate in the
vaccinated population is 15% at its highest, we would need a sam-
ple size between 227 and 1348. We  assumed that the response
rate would be around 50%. We  therefore selected a simple random
sample of 2000 students attending lectures between 24 September
2012 and 11 March 2013 (main cohort). We  chose to select a second
random sample from a speciﬁc population; students who worked
in student bars at least twice a week (student bar-cohort). The bar
managers from the 10 largest student bars were asked to distribute
the survey.2.2.2. Case deﬁnition
For the purpose of surveillance, we  deﬁned a case as any student
at the KU Leuven with self-reported swelling and inﬂammation of
T. Braeye et al. / Vaccine 32 (2014) 4393–4398 4395
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arch 2013.
.2.3. Data collection
We collected information on personal characteristics (age,
ender), mumps-related symptoms (using visual prompts), compli-
ations, possible previous mumps  infections, contact with mumps
ases, days absent from social activities, contact with health care
roviders and self-reported immunization status. We  used a web-
ased questionnaire (Lime survey software, version 1.91). We  sent
nvitations to the selected students on the 18th of March 2013,
ollowed by a reminder one week later. We  reviewed the medical
les of the university medical service to obtain the documented
mmunization status of participants.
.2.4. Data analysis
We described mumps  cases by time, place and person. We  cal-
ulated relative risks (RR) of mumps  according to immunization
tatus and a selection of risk factors along with 95% conﬁdence
ntervals. We  considered a p-value <0.05 as statistically signiﬁcant.
e  extrapolated the incidence of self-reported parotitis to the com-
lete student population of the KU Leuven. We  calculated vaccine
ffectiveness (VE) as the difference in attack rate between those
accinated twice and those vaccinated once over the attack rate in
hose vaccinated once. We  calculated the time in years since the
econd vaccination based on the documented vaccination data.
We analyzed data using STATA 12.00 (STATA Corporation, Col-
ege Station, TX, USA) and SAS 9.3 (SAS Institute Inc. 2011, TX, USA)..2.5. Human subject protection
Informed consent from all students who were included in the
tudy was obtained. On December 14, 2012, the ethics committee
f the hospital of KU Leuven approved the study protocol.
ig. 2. Reported cases of mumps  per municipality, mandatory notiﬁcation data 16/06/20
he  location of colleges, Flanders, Belgium, 2012/2013 (For interpretation of the referen
rticle.).n from 16/06/2012 until 16/04/2013, Flanders, Belgium.
3. Results
3.1. Surveillance data
3.1.1. Epidemiology
Between June 16, 2012 and April 16, 2013, 4052 cases were
reported from Flanders, of which 1187 were possible, 1294 were
probable and 1540 were laboratory-conﬁrmed (overall reported
rates: 31.5/100,000 population). Reported cases of mumps peaked
in December 2012 (Fig. 1). Most cases were reported in cities where
universities are located, including Ghent (n = 510), Leuven (n = 419),
Kortrijk (n = 415) and Antwerp (n = 365) (Fig. 2). Fifty-eight percent
(n = 2364) of the cases were male and 58% (n = 2348) were between
15 and 25 years of age. Vaccination information was available for
1190 (29%) cases. Of these, 70% (n = 836) were vaccinated twice, 28%
(n = 338) were vaccinated once and 2% (n = 16) were unvaccinated.
Orchitis was reported in 11% (n = 145) of male cases for whom the
status of complications was  known. Other complications included
meningitis (n = 8; 0.2%) and pancreatitis (n = 5; 0.1%).
3.1.2. Laboratory results
Between June 16, 2012 and April 16, 2013, 128 specimens were
collected from Flanders and tested for mumps virus at the NRC.
All specimens were tested by PCR; 53% were conﬁrmed. Genotyp-
ing was  performed in41 specimens. All, including the15 specimens
received from the medical service of the KU Leuven, were geno-
typed as G5 (subtype Groningen 2010).
3.2. Retrospective cohort study3.2.1. Description of the outbreak
Of the 2000 students approached, 717 completed the web-
based questionnaire (response = 36%);47 of the students frequently
12 until 16/04/2013. Pink dot depicts the location of the universities and blue dots
ces to color in this ﬁgure legend, the reader is referred to the web  version of the
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orking in student bars responded. Sixty-ﬁve percent (n = 496) of
he respondents were female and the median age was  22 years
range 17–59).
Of the 717 respondents in the main cohort, 38 students
eported parotitis (5.0%, CI 4.4–7.8%), suggesting that 2000 (95%CI
662–2378) parotitis cases may  have occurred among all 37,742
U Leuven students in a period of seven months.
Eighty-two percent (n = 31) and 71% (n = 27) of the cases
eported pain while swallowing and earache, respectively. Other
ymptoms frequently reported by the cases included headache
n = 26; 68%), fever (n = 22; 58%) and fatigue (n = 20; 53%). Two (8%)
f the male cases reported orchitis and two (4%) cases reported
eningitis; 34 (72%) cases visited a physician and one case was
ospitalized.
Mumps  cases started to occur from October 2012, peaked at
he end of December, decreased during the Christmas holidays
nd exams and re-increased in February 2013 as classes resumed
Fig 3).
The median age of cases was 21.5 years (range 18–26) and 53%
n = 25) were male. No signiﬁcant differences were found between
he main cohort and the student bar-cohort. The gender-speciﬁc
ttack rate was 4% for females and 9% for males (RR: 2.1, 95%CI
.2–3.7). The duration of mumps  symptoms ranged from 1 to 20
ays (median: 6.5 days) while absences from classes ranged from
 to 20 days (median: 4.4 days).
The risk of mumps  was higher among students working in stu-
ent bars (9/47, 19%) than among others (38/717, 5%, RR: 3.6, 95%CI
.9–7.0). Even after adjustment for documented immunization sta-
us the RR differed signiﬁcantly from one (adjusted RR: 3.4; 95%CI
.1–11)..2.2. Vaccination status and vaccine effectiveness
Of all study participants, 95% (n = 729) reported their vacci-
ation status. Of those, 3% (n = 30) reported that they had not
able 1
isk of mumps by vaccination status, KU Leuven, Flanders, Belgium, 2012–2013.
Exposures categories Number of
doses
Number of
cases
Total % 
Self-reported
vaccination
0 0 30 0 
1  24 290 8 
2  21 412 5 
Documented
vaccination
0  0 0 0 
1  2 12 17
2  13 247 5 
Time  since second dose (years) 0–10
≥11
4
11
132
122
3
9
a Non applicable.sity of Leuven, Leuven, 24/09/2012–11/03/2013.
been vaccinated, 37% (n = 290) reported being vaccinated once
and 54% (n = 412) reported being vaccinated twice (Table 1). For
33% (n = 259) of the respondents, documented vaccination status
was available in the medical ﬁles of the KU Leuven. Among those
with a documented vaccination status, none were unvaccinated, 5%
(n = 12) were vaccinated once and 95% (n = 247) twice. The risk of
mumps  among students who were vaccinated twice (attack rate 5%)
was lower than among those who  were vaccinated once (attack rate
17%). The two dose vaccine effectiveness, as compared to a single
dose, was  estimated at 68% (RR: 0.32, 95%CI −24% to 92%).
The risk of mumps  among those vaccinated with two doses
within the last 10 years (attack rate 3%) was  lower than among
those vaccinated with two doses ≥11 years earlier (attack rate 9%).
The difference was not signiﬁcant (95%CI 0.10–1.02).
4. Discussion
Between June 2012 and April 2013, the Flemish region of
Belgium reported an increased number of mumps cases, mostly
among young vaccinated adults and in cities with universities. At
the end of 2012, a mumps  outbreak occurred among highly vacci-
nated students in the largest university of Flanders. The estimated
vaccine effectiveness for mumps  for two doses compared to one
was 68% (95%CI −24% to 92%), with indications of waning immunity
over time.
We  estimated an attack rate of mumps  of 5% during this out-
break. This ﬁnding was  consistent with results of several other
European studies in similar settings, where the reported attack
rates of mumps  ranged from 1% to 7% among vaccinated popu-
lations [10,21]. However, in the Netherlands, during an outbreak
among university students, the attack rate was higher (13%) [11].
Mandatory notiﬁcation and cohort study data suggested that
the incidence was higher among males. This may  have an immuno-
logical explanation. In vitro studies indicated that females have a
Relative
risk
95% Conﬁdence
interval
Vaccine
effectiveness %
95% Conﬁdence
interval
N/A N/A N/Aa N/A
Reference Reference Reference Reference
0.61 0.34–1.07 39 −7.4 to 66
N/A N/A N/A N/A
 Reference Reference Reference Reference
0.32 0.08–1.24 68 −24 to 92
0.33
Reference
0.10–1.02
Reference
67
Reference
0–89
Reference
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reater immune response to vaccination than males [22]. More-
ver, seroprevalence studies conducted in the Netherlands and
elgium reported lower levels of mumps-induced antibodies in
ales [23,24].
The documented vaccination coverage for two-doses of mumps-
ontaining vaccine among our study participants was  95%.
eroprevalence studies suggest that a two-dose coverage of
95%for mumps  protects populations from outbreaks [25,26]. In
012, a vaccination coverage survey in the Flemish region reported
2.5% coverage for the second dose of MMR  [17]. A coverage sur-
ey, conducted in 2005, among the birth cohort that was  highly
ffected during the 2013 outbreak (birth year: 1991) estimated a
accination coverage of 84% for the second dose [27]. Therefore,
he vaccination coverage in Flanders may  have been insufﬁcient
o protect the population against outbreaks. The low proportion of
articipants for whom medical ﬁles were available at the university
edical service may  have biased our vaccination coverage.
In our study, we could not obtain a signiﬁcant vaccine effective-
ess estimate. We  obtained a vaccine effectiveness estimate of 68%
or the second dose as compared to only one dose, indicating the
eneﬁt of vaccinating twice, but also indicating that a two  dose vac-
ination offers incomplete protection. Results of a 2012 Cochrane
eview indicated a two-dose vaccine effectiveness of 83–88% for
ab-conﬁrmed cases [28]. In outbreak situations, case deﬁnitions
nd determination of vaccination status may  inﬂuence the vaccine
ffectiveness estimates.
Differences between the wild type virus and the vaccine strain
ay  also explain the low vaccine effectiveness estimate in our
tudy. Low antibody avidity to wild-type virus, as the mismatch
etween the vaccine genotype and that of the circulating mumps
irus strains may  facilitate immune escape [29]. In our study, all iso-
ates were genotyped as G5, suggesting that this was the circulating
ild type virus. Reports indicated that cross-protection between
he vaccine genotype A and the circulating wild strains (mainly C, D
nd G) is incomplete. However, other studies have documented that
linical isolates were successfully neutralized by vaccine induced
mmunity and a higher avidity of mumps  antibodies was observed
mongst vaccinated cases [30].
Waning immunity could also explain our effectiveness estimate.
hose who were vaccinated more than 10 years earlier were at
reater risk of developing mumps  than those vaccinated later, this
imple analysis is however limited, since no correction for pos-
ible confounding factors is done. Other studies report diverse
esults on waning immunity. A 2003 Belgian study and a 2006
tudy in the USA, both in outbreak settings, reported that protection
gainst mumps  declined with increasing time since last vaccination
6,31,32].
A speciﬁc second sample of students frequently working in bars
as compared to the ﬁrst random sample of students. The main
urpose of this design was to evaluate if dense social contacts would
ffect attack rates. We  felt that the response rate on our survey
ould suffers from questions such as time spent in student bars and
lso that the quality of answers on such questions might be low. We
herefore selected a second cohort. This second cohort worked in
tudent bars for 2–3 evenings a week. This was used as a proxy for
ense social contacts. Differentiating student bar workers from the
ther students in the ﬁrst sample would have also been possible, but
ould have required a much larger ﬁrst sample, since only a small
roportion of students worked in bars. No students were present
n both cohorts. It is possible that confounders were present as the
econd cohort might differ from the general student population
n more than working in bars often crowded with a lot of peers.
ge, gender and vaccination coverage were however comparable
etween cohorts. We  found a higher attack rate in students work-
ng in student bars as compared to the general student population.
ther studies in populations with a high coverage of two doses (2014) 4393–4398 4397
of mumps-containing vaccine have also reported close and pro-
longed social contacts as an important risk factor for transmission
[9]. Intense social contacts in close environments may  contribute
to over come vaccine-induced protection. Avoiding these whilst
infectious will limit the spread of a mumps outbreak. An impor-
tant limitation of such a control measure is however that persons
might be infectious up to 6 days before exhibiting symptoms [33].
The speciﬁc contribution of social activities in overcoming vaccine
induced protection, certainly if this protection is incomplete due to
vaccine effectiveness, incomplete coverage and waning, is a topic
for further research.
Our study is subject to certain limitations. First, our use of
self-reported clinical symptoms de facto consisted in parotitis
surveillance. Mumps  can be asymptomatic, without parotitis, and
on the other hand parotitis can be caused by other pathogens,
especially when incidence of other respiratory infections is high.
This may  have underestimated or overestimated the incidence
of mumps. The clinical deﬁnition of mumps  as uni- or bilateral
swelling of the parotis or any other salivary gland for a minimum
of two  days without a known cause is however highly speciﬁc for
mumps  in outbreak settings. Using only laboratory conﬁrmed cases
also had limitation since laboratory conﬁrmation is challenging in
highly vaccinated populations [34]. Second, the low response rate
(36%) may  have introduced selection bias. E.g. those who  suffered
might be more willing to answer the questioner than others.
Third, availability of documented vaccination data was limited.
The low proportion of participants for whom medical ﬁles were
available at the university has resulted in large conﬁdence intervals
for vaccine effectiveness. Based on the documented vaccination
status we  were not able to compare fully vaccinated students to
unvaccinated students, since no students were documented as
unvaccinated. These small numbers are a limitation and do not
allow us to sufﬁciently quantify vaccine effectiveness. The availabil-
ity of vaccination records will change in the near future, as almost
all relevant data will be stored in the newly created immunization
database “Vaccinnet” for Flanders [35].
5. Conclusions and recommendations
A large mumps  outbreak affected vaccinated young adults in
Flanders. Incomplete protection by the mumps  component of the
MMR vaccine, possible waning immunity over time and the intense
social contacts may  have contributed to the occurrence of a mumps
outbreak in the highly vaccinated student population in Flanders.
As the risk for mumps  was  higher in students working in bars,
we conclude that social activities play an important role in the
transmission of mumps. The advice to avoid social activities whilst
infectious should be given to all possible cases. The main preventive
measure remains vaccination and efforts towards a high vaccina-
tion coverage (>95%) remain essential. The reasons for outbreaks in
highly vaccinated populations must however be further explored
and additional immunological research towards more immuno-
genic mumps vaccines is necessary.
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